Autosomal Dominant Polycystic Kidney Disease Clinical Trial
Official title:
A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease
The purpose of this study is to compare SOM230 treatment to placebo. The investigators will also assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life.
Pasireotide (SOM230) is a novel multi-receptor-targeted analog that has high affinity for
four of the five SST receptor subtypes (SSTr1, SSTr2, SSTr3 and SSTr5); it has a 40-fold
higher affinity and 158-fold higher functional activity for the SST5 receptor than
octreotide. Because of its broad receptor binding profile, pasireotide may be more potent in
Polycystic Liver Disease (PLD) than octreotide. In this randomized double blind placebo
controlled trial the investigators will compare SOM230 treatment to placebo for 12 months in
patients with PLD. The primary endpoints will be assessed at 12 months and patients receiving
placebo then crossed over to SOM230, permitting all participants to receive SOM230 for the
subsequent two years. Magnetic resonance imaging (MRI) will be used to assess liver volume -
the primary endpoint, which will be assessed at baseline, end of years 1 and 3. This study
will assess the efficacy and safety of SOM230 in reducing total liver volume and improving
quality of life over 12 months. (The investigators will not be assessing efficacy at 24
months.) The therapy way be effective in PLD but also may prove to be effective for many more
patients with Polycystic Kidney Disease (PKD) which will be evaluated using eGFR and kidney
volume using MRI.
The investigators plan to add other sub-sites in other locations.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02933268 -
High Water Intake in Polycystic Kidney Disease
|
N/A | |
| Completed |
NCT00759369 -
Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
N/A | |
| Completed |
NCT00598377 -
Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
| Completed |
NCT01039987 -
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease
|
N/A | |
| Completed |
NCT03717883 -
ADPKD Alterations in Hepatic Transporter Function
|
||
| Recruiting |
NCT05193981 -
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
|
||
| Completed |
NCT03487913 -
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 2 | |
| Not yet recruiting |
NCT06435858 -
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
|
Phase 4 | |
| Recruiting |
NCT05190744 -
PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
|
Phase 2 | |
| Recruiting |
NCT05521191 -
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1 | |
| Recruiting |
NCT04344769 -
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
||
| Active, not recruiting |
NCT02848521 -
A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
|
||
| Completed |
NCT01451827 -
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 2 | |
| Completed |
NCT01210560 -
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
|
Phase 2 | |
| Completed |
NCT01336972 -
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 2 | |
| Completed |
NCT02134899 -
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
|
Phase 3 | |
| Active, not recruiting |
NCT02729662 -
Efficacy of Tolvaptan on ADPKD Patients
|
N/A | |
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Recruiting |
NCT05288998 -
Intrarenal Microvasculature in ADPKD
|
||
| Recruiting |
NCT04939935 -
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
|
Phase 3 |